focus -WSS

focus

author：Wikipedia 2025-09-14 11:51:14 - browse：3885

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： GOP presidential candidates start declaring their loyalty

WSS

Medicare’s new pay boost for primary care is angering specialists

Type 2 diabetes prevention programs work at large scale: study

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Study suggests Covid rebound is far more common with Paxlovid than without

After John Oliver segment, STAT readers share their opioid

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

Cancer diagnosis changes perspective doctor, former hospital CEO

Jerome Adams on the need for new antivirals for Covid

Ventyx halts psoriasis drug development after lackluster trial results

BioMarin wins approval for gene therapy to treat hemophilia A

Medical school prerequisites are outdated

How to save PrEP access — and even expand it

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Bright Health sells Medicare Advantage business to Molina

Listen: Your guide to Wegovy's blockbuster heart study

knowledge

An innovative path out of biotech’s “valley of death”

NIH chief: government has fallen behind pharma on clinical trials

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Study suggests Covid rebound is far more common with Paxlovid than without

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Large hospital system sues Multiplan for low

hotspot

entertainment

knowledge

focus